Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.1
3.9
Journals
Life
Special Issues
Management of Inflammatory Airway Diseases
share announcement

Management of Inflammatory Airway Diseases

A Special Issue of Life (ISSN 2075-1729) belonging to the section "Medical Research".

Deadline for manuscript submissions: closed (31 August 2026) | Viewed by 818

Editors

Dr. Diego Bagnasco

E-Mail
Guest Editor
Department of Internal Medicine (DIMI), University of Genoa, 16132 Genoa, Italy
Interests: asthma; severe asthma; lung disease; lung physiopathology; T2 inflammation; rhinosinusitis; nasal polyps
Special Issues, Collections and Topics in MDPI journals
Dr. Benedetta Bondi

E-Mail Website
Guest Editor Assistant
Department of Internal Medicine (DIMI), University of Genoa, 16132 Genoa, Italy
Interests: asthma; enviroment; obstuctive diseases; microplastics; inflammation; monoclonal antibodies

Special Issue Information

Dear Colleagues,

Inflammatory airway diseases represent a rapidly evolving field in which molecular, immunological, and clinical insights are reshaping diagnostic and therapeutic strategies. Conditions such as asthma, chronic rhinosinusitis, COPD, EGPA and overlapping inflammatory phenotypes continue to challenge clinicians and researchers due to their heterogeneity and complex pathophysiology.

This Special Issue of Life, titled 'Management of Inflammatory Airway Diseases', aims to gather high-quality contributions that explore innovative approaches to understanding, diagnosing, and treating airway inflammation. We welcome original research, clinical studies, translational investigations, systematic reviews, meta-analyses, and well-documented case reports.

We are particularly interested in papers that focus on molecular mechanisms of inflammation, biomarkers for disease stratification, therapeutic targets, biologics, small molecules, inhaled therapies, and integrated management strategies. Contributions addressing treatable traits, precision medicine, comorbidities, and long-term disease control are strongly encouraged.

Our goal is to provide a comprehensive and multidisciplinary platform that advances knowledge and supports clinicians and researchers in improving patient outcomes.

Dr. Diego Bagnasco
Guest Editor

Dr. Benedetta Bondi
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory airway diseases
  • asthma
  • EGPA
  • COPD
  • chronic rhinosinusitis
  • biomarkers
  • biologics
  • treatable traits
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 373 KB  
Article
Trajectories in Oxidative Stress and Corticosteroids Insensitivity in Patient with High Risk of Severe Asthma: Use of FeNO as Biomarker of Respiratory Epithelial Barrier Distress
by Cristiano Caruso, Ilaria Baglivo, Emanuele Cataldo, Ludovica Fabbroni, Maria Antonietta Zavarella, Stefania Colantuono, Gianna Camiciottoli, Giovanna Elisiana Carpagnano, Antonio Di Marco, Loreta Di Michele, Fabiana Furci, Chiara Magni, Laura Martino, Alessandro Mastinu, Corrado Micucci, Nicola Scichilone, Roberto Tazza, Rodolfo Pacilio and Michele Miraglia Del Giudice
Life 2026, 16(7), 1203; https://doi.org/10.3390/life16071203 - 21 Jul 2026
Viewed by 444
Abstract
Background: Precision medicine targets clinical remission, but traditional symptom-based frameworks often ignore the biological pathways driving the disease. Adequate T2 biomarker interpretation is crucial to identify phenotypes where FeNO reflects epithelial barrier distress. We investigated the “clinical-biological gap” through the analysis of six [...] Read more.
Background: Precision medicine targets clinical remission, but traditional symptom-based frameworks often ignore the biological pathways driving the disease. Adequate T2 biomarker interpretation is crucial to identify phenotypes where FeNO reflects epithelial barrier distress. We investigated the “clinical-biological gap” through the analysis of six groups to distinguish profiles of symptomatic resilience from biological insensitivity to corticosteroids. Methods: Real-world study of 292 patients stratified into six groups based on BEC (≥250 cells/microL), FeNO (≥25 ppb), and IgE (≥100 kU/L). ACT, BMI, FEV1, comorbidities, and therapeutic burden were analyzed. Results: The EoS+ IgE+ group showed “symptomatic resilience”: apparent clinical control (54.5% ACT ≥ 20) supported by a critical pharmacological burden (90% salbutamol, 80% OCS ≥ 7.5 mg). The Triple Positive and EoS+ FeNO+ groups depicted “Maximum Steroid Insensitivity,” characterized by poor control despite maximal ICS/OCS regimens. FeNO could appear like the primary driver of instability, reflecting a trajectory of oxidative stress not altered by steroids. Conclusions: T2 biomarkers provide a unique prognostic value unidentifiable by standard clinical assessment. FeNO monitoring unmasks silent distress in resilient patients and identifies the “therapeutic wall” in refractory profiles. Therefore biological remission could represents the only effective target to modify the natural history of the disease. Full article
(This article belongs to the Special Issue Management of Inflammatory Airway Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop